{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:38:32Z","timestamp":1789763912235,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jaut.2014.07.003","type":"journal-article","created":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T19:46:42Z","timestamp":1409255202000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis \u2013 Xenograft model"],"prefix":"10.1016","volume":"55","author":[{"given":"Smriti","family":"Kundu-Raychaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Je","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siba P.","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2014.07.003_bib1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1468-3083.2001.00192.x","article-title":"The prevalence of psoriasis in the world","volume":"15","author":"Raychaudhuri","year":"2001","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.jaut.2014.07.003_bib2","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2014.07.003_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3899\/jrheum.120237","article-title":"Metabolic syndrome in patients with psoriatic disease","volume":"89","author":"Gelfand","year":"2012","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.jaut.2014.07.003_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3899\/jrheum.111244","article-title":"Comorbidities of psoriatic arthritis \u2013 metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting","volume":"39","author":"Raychaudhuri","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib5","first-page":"939","article-title":"Biologicals in the treatment of psoriasis","volume":"8","author":"Boker","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.jaut.2014.07.003_bib6","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature03727","article-title":"Design of effective immunotherapy for human autoimmunity","volume":"435","author":"Feldmann","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2014.07.003_bib7","article-title":"Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points","author":"Puig","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaut.2014.07.003_bib8","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1038\/492S58a","article-title":"Therapeutics: silencing psoriasis","volume":"492","author":"Crow","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2014.07.003_bib9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/jid.2009.247","article-title":"Skin-resident T cells: the ups and downs of on site immunity","volume":"130","author":"Clark","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s004030000167","article-title":"Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory effector\/type 1 immunophenotype","volume":"292","author":"Friedrich","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaut.2014.07.003_bib11","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2133.2004.05863.x","article-title":"Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late","volume":"150","author":"Vissers","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jaut.2014.07.003_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.2009.00816.x","article-title":"The functional network of ion channels in T lymphocytes","volume":"231","author":"Cahalan","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaut.2014.07.003_bib14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1172\/JCI16921","article-title":"The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS","volume":"111","author":"Wulff","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2014.07.003_bib15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1124\/mol.104.008193","article-title":"Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases","volume":"67","author":"Beeton","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jaut.2014.07.003_bib16","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0605136103","article-title":"Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases","volume":"103","author":"Beeton","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2014.07.003_bib17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.immuni.2008.07.015","article-title":"Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block","volume":"29","author":"Matheu","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2014.07.003_bib18","doi-asserted-by":"crossref","first-page":"F1258","DOI":"10.1152\/ajprenal.00374.2010","article-title":"Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis","volume":"299","author":"Hyodo","year":"2010","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.jaut.2014.07.003_bib19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.112.191890","article-title":"Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease","volume":"342","author":"Tarcha","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jaut.2014.07.003_bib20","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.4049\/jimmunol.1103095","article-title":"Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis","volume":"188","author":"Gocke","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2014.07.003_bib21","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.jid.5700717","article-title":"Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis","volume":"127","author":"Azam","year":"2007","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaut.2014.07.003_bib23","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaut.2014.07.003_bib24","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/jid.2008.38","article-title":"FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model","volume":"128","author":"Raychaudhuri","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1046\/j.1365-2133.2001.04219.x","article-title":"Cellular localization of fractalkine at sites of inflammation: antigen-presenting cells in psoriasis express high levels of fractalkine","volume":"144","author":"Raychaudhuri","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib26","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1073\/pnas.91.20.9282","article-title":"CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and\/or V beta 13.1 genes","volume":"91","author":"Chang","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2014.07.003_bib27","doi-asserted-by":"crossref","first-page":"11094","DOI":"10.1073\/pnas.0501770102","article-title":"The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain","volume":"102","author":"Rus","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaut.2014.07.003_bib28","first-page":"580","article-title":"Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model","volume":"146","author":"Nickoloff","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaut.2014.07.003_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1689","article-title":"Getting under the skin: the immunogenetics of psoriasis","volume":"5","author":"Bowcock","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaut.2014.07.003_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.jaut.2014.07.003_bib31","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1067\/mjd.2000.107945","article-title":"Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study","volume":"43","author":"Gottlieb","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib33","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1172\/JCI118989","article-title":"Dermal injection of immunocytes induces psoriasis","volume":"98","author":"Wrone-Smith","year":"1996","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2014.07.003_bib34","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1124\/mol.105.015669","article-title":"Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases","volume":"68","author":"Schmitz","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jaut.2014.07.003_bib35","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1021\/cr078234p","article-title":"K+ channel modulators for the treatment of neurological disorders and autoimmune diseases","volume":"108","author":"Wulff","year":"2008","journal-title":"Chem Rev"},{"key":"10.1016\/j.jaut.2014.07.003_bib36","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nrd2983","article-title":"Voltage-gated potassium channels as therapeutic targets","volume":"8","author":"Wulff","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaut.2014.07.003_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.toxicon.2011.07.016","article-title":"Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases","volume":"59","author":"Chi","year":"2012","journal-title":"Toxicon"},{"key":"10.1016\/j.jaut.2014.07.003_bib38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/386855a0","article-title":"Differential activation of transcription factors induced by Ca2+ response amplitude and duration","volume":"386","author":"Dolmetsch","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2014.07.003_bib39","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nri2152","article-title":"Calcium signalling in lymphocyte activation and disease","volume":"7","author":"Feske","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaut.2014.07.003_bib40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tips.2004.03.010","article-title":"Potassium channels as targets for specific immunomodulation","volume":"25","author":"Chandy","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jaut.2014.07.003_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s004030050391","article-title":"The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs","volume":"291","author":"Boehncke","year":"1999","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaut.2014.07.003_bib42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nm0402-366","article-title":"Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation","volume":"8","author":"Schon","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2014.07.003_bib43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/jid.2010.245","article-title":"The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model","volume":"131","author":"Gilhar","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaut.2014.07.003_bib44","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0896-6273(03)00844-4","article-title":"Kv1.3 channel gene-targeted deletion produces \u201cSuper-Smeller Mice\u201d with altered glomeruli, interacting scaffolding proteins, and biophysics","volume":"41","author":"Fadool","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.jaut.2014.07.003_bib45","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1002\/cne.22393","article-title":"Localization of Kv1.3 channels in presynaptic terminals of brainstem auditory neurons","volume":"518","author":"Gazula","year":"2010","journal-title":"J\u00a0Comp Neurol"},{"key":"10.1016\/j.jaut.2014.07.003_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/ana.20884","article-title":"Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system","volume":"60","author":"Mullen","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2014.07.003_bib47","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.4049\/jimmunol.0803003","article-title":"Developmental switch of the expression of ion channels in human dendritic cells","volume":"183","author":"Zsiros","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2014.07.003_bib48","doi-asserted-by":"crossref","first-page":"46307","DOI":"10.1074\/jbc.M304388200","article-title":"Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages","volume":"278","author":"Vicente","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaut.2014.07.003_bib49","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1038\/jid.2013.141","article-title":"Blocking potassium channels (Kv1.3): a new treatment option for alopecia areata?","volume":"133","author":"Gilhar","year":"2013","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841114001164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841114001164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:10:06Z","timestamp":1760256606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841114001164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":49,"alternative-id":["S0896841114001164"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2014.07.003","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis \u2013 Xenograft model","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2014.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}